Gilead Sciences, Inc. (GILD) Stock Valuation — PE Analysis
Drug Manufacturers - General · NASDAQ
Current Price
$146.12
PE Ratio (TTM)
n/m
Intrinsic Value
Use the calculator below to estimate
COMPETITIVE MOAT
↑Dominant HIV Franchise
Gilead's long-standing leadership in HIV treatment, with drugs like Biktarvy, creates significant patient and physician loyalty. This established market position is difficult for competitors to dislodge.
↑Strong Oncology Pipeline
Investments in oncology, including recent advancements, offer potential for future blockbuster drugs. This diversification reduces reliance on any single therapeutic area.
↑Patented Drug Portfolio
Gilead holds patents on key revenue-generating drugs, providing a period of exclusivity and pricing power. This protects its market share from generic competition.
INVESTMENT RISKS
↓Clinical Trial Failures
The success of pharmaceutical companies hinges on the outcomes of clinical trials. A failure in a key drug development program could significantly impact future revenue.
↓Competition in Oncology
The oncology market is highly competitive with numerous players investing heavily in research and development. New entrants or breakthroughs could challenge Gilead's position.
↓Integration of Acquisitions
While acquisitions can bolster the pipeline, integrating new assets and realizing synergies can be challenging. Poor integration could lead to underperformance.
Customize the GILD PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Gilead Sciences, Inc. respond.
Open PE Calculator for GILDCompany Overview
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Financial Metrics — GILD PE Stock Valuation Data
PE Ratio (TTM)
n/m
PEG Ratio
0.37
Earnings Yield
-1.78%
ROE (TTM)
-16.3%
Revenue/Share (TTM)
$24.50
Dividend Yield
2.20%
Debt/Equity
2.22x
Frequently Asked Questions
What is the PE ratio of GILD?
The trailing twelve-month PE ratio of GILD reflects how much investors pay per dollar of Gilead Sciences, Inc.'s earnings. This metric is most useful when compared to Drug Manufacturers - General peers and the company's own historical range.
Is GILD overvalued based on PE ratio?
GILD's PE of -56.2x combined with a PEG ratio of 0.37 provides a growth-adjusted perspective. A PEG below 1.0 means the P/E is low relative to the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Drug Manufacturers - General, a DCF analysis may be more appropriate.
How do I value GILD stock using PE ratio?
To value Gilead Sciences, Inc. using PE: (1) Compare the current PE (-56.2x) against the Drug Manufacturers - General median to assess relative pricing, (2) check the PEG ratio (0.37) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of GILD?
GILD's PEG ratio is 0.37, calculated by dividing the PE ratio (-56.2x) by the expected earnings growth rate. A PEG below 1.0 means the P/E is low relative to the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for GILD stock valuation?
PE ratio gives a quick relative read — how GILD is priced versus Drug Manufacturers - General peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See GILD DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value GILD with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-08-21. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.